Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Upgraded by BidaskClub

Dovie Salais

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, BidAskClub reports. A number of other equities research analysts have also recently weighed in on BCYC. Cantor Fitzgerald started coverage on Bicycle Therapeutics in a research note […]

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, BidAskClub reports.

A number of other equities research analysts have also recently weighed in on BCYC. Cantor Fitzgerald started coverage on Bicycle Therapeutics in a research note on Monday, October 12th. They set an “overweight” rating and a $30.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, August 6th. Zacks Investment Research cut Bicycle Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 28th. Oppenheimer reiterated a “buy” rating and issued a $27.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday, September 22nd. Finally, Canaccord Genuity increased their price target on Bicycle Therapeutics from $23.50 to $25.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $23.67.

BCYC opened at $18.51 on Friday. The company has a market capitalization of $327.63 million, a PE ratio of -8.90 and a beta of -0.42. The firm has a 50-day simple moving average of $18.98 and a two-hundred day simple moving average of $16.92. Bicycle Therapeutics has a 52 week low of $7.50 and a 52 week high of $21.59.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Wednesday, August 5th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.19). The firm had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $2.11 million. Bicycle Therapeutics had a negative return on equity of 43.74% and a negative net margin of 434.29%. As a group, analysts forecast that Bicycle Therapeutics will post -2.49 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in BCYC. FMR LLC acquired a new stake in Bicycle Therapeutics during the 2nd quarter valued at approximately $3,277,000. Advisor Group Holdings Inc. grew its holdings in shares of Bicycle Therapeutics by 34,000.0% during the second quarter. Advisor Group Holdings Inc. now owns 34,100 shares of the company’s stock worth $537,000 after buying an additional 34,000 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Bicycle Therapeutics during the first quarter worth $179,000. Morgan Stanley grew its holdings in shares of Bicycle Therapeutics by 32,450.0% during the first quarter. Morgan Stanley now owns 3,255 shares of the company’s stock worth $44,000 after buying an additional 3,245 shares in the last quarter. Finally, UBS Group AG purchased a new stake in shares of Bicycle Therapeutics during the second quarter worth $36,000. Institutional investors and hedge funds own 35.54% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Further Reading: Understanding the different types of bonds

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source Article

Next Post

Who Is the Average Car Buyer?

October’s issue includes our annual 20 Questions feature. You can find these and 17 other questions–and answers–there. Automakers use the desires of the average car buyer to justify many decisions, from the brief but glorious trend for plaid upholstery to the fact that almost every passenger vehicle sold in the […]

Subscribe US Now